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Background: Phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] is an important regulator of several cel-
lular processes and a precursor for other second messengers which are involved in cell signaling path-
ways. Signaling proteins preferably interact with PI(4,5)P2 through its pleckstrin homology (PH) domain.
Efforts are underway to design small molecule-based antagonist, which can speciﬁcally inhibit the PI(4,5)
P2/PH-domain interaction to establish an alternate strategy for the development of drug(s) for phos-
phoinositide signaling pathways.
Methods: Surface plasmon resonance, molecular docking, circular dichroism, competitive Förster re-
sonance energy transfer, isothermal titration calorimetric analyses and liposome pull down assay were
used.
Results: In this study, we employed 1,2,3-triazol-4-yl methanol containing small molecule (CIPs) as an-
tagonists for PI(4,5)P2/PH-domain interaction and determined their inhibitory effect by using competi-
tive-surface plasmon resonance analysis (IC50 ranges from 53 to 159 nM for PI(4,5)P2/PLCδ1-PH domain
binding assay). We also used phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3], phosphatidylinositol
3,4-bisphosphate [PI(3,4)P2], PI(4,5)P2 speciﬁc PH-domains to determine binding selectivity of the
compounds. Various physicochemical analyses showed that the compounds have weak affect on ﬂuidity
of the model membrane but, strongly interact with the phospholipase C δ1 (PLCδ1)-PH domains. The
1,2,3-triazol-4-yl methanol moiety and nitro group of the compounds are essential for their exothermic
interaction with the PH-domains. Potent compound can efﬁciently displace PLCδ1-PH domain from
plasma membrane to cytosol in A549 cells.
Conclusions: Overall, our studies demonstrate that these compounds interact with the PIP-binding PH-
domains and inhibit their membrane recruitment.
General signiﬁcance: These results suggest speciﬁc but differential binding of these compounds to the
PLCδ1-PH domain and emphasize the role of their structural differences in binding parameters. These
triazole-based compounds could be directly used/further developed as potential inhibitor for PH do-
main-dependent enzyme activity.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In response to speciﬁc stimuli, various cytosolic proteins are
reversibly recruited to the cellular membranes and form dynamic
signaling complexes with speciﬁc lipid molecules, including phos-
phatidylinositols (PIPs). The PIP lipids have drawn considerableB.V. This is an open access article uattention due to their various cellular functions through a plethora of
effector proteins [1–4]. A range of human diseases which are directly
or indirectly linked with PIP-binding/metabolism have been identiﬁed
and become an exciting therapeutic target in biomedical research
[2,3,5–8]. Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) is the
most abundant PIP in the plasma membrane (PM). Hydrolysis of PI
(4,5)P2 to diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3)
by activated phospholipase C (PLC) enzymes is one of the crucial
cellular signaling pathways. IP3 regulates Ca2þ release fromnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nase C (PKC) enzymes. Various membrane receptors including
G-protein-coupled receptors (GPCRs) strongly interact with PLC
enzyme and regulate PI(4,5)P2 turnover and consequent down-
stream cell signaling pathways. PI(4,5)P2 regulates several proteins
including PLCδ, Ras GTPase activating protein (RasGAP) and pleck-
strin, which also mediate a wide verity of cellular process [9–12].
Improper cellular functions of these effectors proteins are associated
with disorder such as neurodegenerative, cardiovascular diseases
and others [13,14]. The PI-kinase I/II and SH2-containing Inositol-5′-
Phosphatase (SHIP), phosphatase and tensin homolog (PTEN) en-
zymes phosphorylate phosphatidylinositol-4-phosphate (PI(4)P)/
phosphatidylinositol-5-phosphate (PI(5)P) and dephosphorylate
phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3), respectively
to generate PI(4,5)P2 at the inner PM in responses to various stimuli
[15,16]. PI(4,5)P2 lipid is phosphorylated by class I PI3-kinase to form
PI(3,4,5)P3, which regulates cellular functions of several crucial sig-
naling proteins including AKT.
The PI(4,5)P2 generation recruits several proteins to the PM
through their interaction with pleckstrin homology (PH)- or other
PIP-binding modules. This PI(4,5)P2-dependent membrane asso-
ciation of the lipid binding modules is necessary and sufﬁcient for
activation and proper functioning of the effector proteins; in-
cluding PLCδ. Activation of PLCδ proceeds only after PI(4,5)P2-
binding of the PH domain at the inner PM that reorient the EF-
hands–C2 domain–TIM barrel unit so that the catalytic domain is
in a productive orientation relative to the membrane. Recent
studies reported that in addition to PH domain, C2 domain of PLCδ
also interacts with the membrane and plays an important role in
PLCδ activation [17,18].
In general catalytic domains of the proteins are considered as
drug target to down/up-regulate the cellular activities by direct in-
hibition/activation mechanism. However, the catalytic activities of
the proteins should be effectively regulated in the cells, because
direct inhibition/activation could also induce side-effects by dis-
rupting the other up/down-stream of the cellular pathways [19–21].
Detailed mechanistic studies demonstrated that highly speciﬁc PIP/
PH-domain interactions can regulate activities of the effector pro-
teins. It is also important to note that the PH-domains contain a
conserved structure with well-deﬁned binding site for “prototypic”
small molecule–protein interaction studies [22]. It is also depicted
that protein–lipid interactions are readily targetable by small mo-
lecules due to the small and deﬁned binding site of the proteins for
speciﬁc lipid molecules, whereas protein–protein interactions nor-
mally need extended ﬂat protein surfaces, that are difﬁcult to disrupt
by small molecules. It is also demonstrated that development of
small molecules based inhibitors for lipid–protein interactions is
advantageous over typical approaches in the aspect of side-effect
and rational design because of relatively simple structures and
functions [5,20,23,24]. For these reasons, the PH-domains of the
effector proteins can be considered as an attractive alternate target
in designing selective inhibitors for its interaction with PIPs.
However, development of inhibitors for PIP/PH-domain inter-
actions to regulate enzyme activities had not been substantially
described yet. Using the similar hypothesis, we recently demon-
strated that development of DAG-responsive C1 domain based
activator can be considered as an alternative target to regulate the
activities of the PKC enzymes [25–27]. Recently developed PH-
domain targeting lipid-based compound, 3-deoxy phosphatidyli-
nositol ether lipid (DPIEL) and PHT-427 were described as poten-
tial drug candidates for the treatment of cancer and other human
diseases [21,28]. Small molecules like PITENINs were also de-
monstrated as the inhibitor of PI(3,4,5)P3 binding of AKT1/PDK1-
PH-domains and down-regulator of PI3-Kinase/PDK1/AKT1 path-
ways [8]. There are only a few PLC regulators that play a signiﬁcant
role in understanding the PI(4,5)P2 mediated cellular signalingpathways [17,29]. Neomycin is known as a regulator of PI(4,5)P2–
PLC enzyme interactions and PLC induced PI(4,5)P2 hydrolysis at
the cellular membranes. However neomycin directly interacts with
the PI(4,5)P2 molecules present at the membrane through an
electrostatic interaction and blocks PLCδ enzyme activity [29].
However, there is no report of PH domain speciﬁc PLC regulator.
In this regard our current study describes the development of
1,2,3-triazol-4-yl methanol-based antagonists, CIPs for PI(4,5)P2/
PLCδ1-PH domain binding. These compounds at lower con-
centrations showed certain degree of selective inhibitory effect
towards different PH-domains used for the current study. The
1,2,3-triazol-4-yl methanol moiety and nitro group of the com-
pounds play a crucial role in distinguishing the PH-domains. Po-
tent compound, CIP-4, can competitively interact with the PLCδ1-
PH domain and displace it from PM to cytoplasm. We believe that
these non-lipid potent compounds would be able to inhibit PI(4,5)
P2 targeted PIP-binding proteins/enzyme under cellular environ-
ment and regulate its cellular signaling pathways.2. Experimental methods
2.1. General Information
All chemicals and reagents were purchased from Sigma (St.
Louis MO), SRL (Mumbai, India), Merck (Mumbai, India) and used
for the synthesis without further puriﬁcation. Phosphatidylinosi-
tol-3,4,5-triphosphate (PI(3,4,5)P3), phosphatidylinositol-3,4 -bi-
sphosphate (PI(3,4)P2) and phosphatidylinositol-4,5-bisphosphate
(PI(4,5)P2) were purchased from Cayman Chemicals (Ann Arbor,
MI). 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (PC), 1,2-di-
palmitoyl-sn-glycero-3-phospho-L-serine (PS), 1,2- dipalmitoyl-sn-
glycero-3-phosphoethanolamine (PE), 1,2-dipalmitoyl-sn-glycero-
3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl)
(NBD-PE) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(5-dimethylamino-1-naphthalenesulfonyl) (dPE) were purchased
from Avanti Polar Lipids. Octyl glucoside was purchased from
Fisher. The Pioneer L1 sensor chip was purchased from Biacore AB
(Piscataway, NJ). Ultrapure water (Milli-Q system, Millipore, Bill-
erica, MA) was used for the preparation of buffers. Compounds
were ﬁrst dissolved in DMSO and then diluted in working buffer so
that overall DMSO concentration was o5% (v/v).
2.2. Protein puriﬁcation
The AKT1 (homo sapiens; 1-121 amino acids), GRP1 (mus
musculus, 1-127 amino acid), TAPP1 (homo sapiens; 180-305
amino acid) and PLCδ1 (rattus norvegicus, 1-131 amino acid) PH-
domains were expressed in Escherichia coli cells (BL21-DE3) and
puriﬁed using methods similar to those reported earlier [22]. The
plasmids were generous gift from Prof. Wonhwa Cho (University of
Illinois at Chicago, IL, USA).
2.3. Surface plasmon resonance (SPR) assay
All surface plasmon resonance (SPR) measurements were per-
formed (at 25 °C, in 20 mM HEPES buffer, pH 7.4, containing 0.16 M
KCl, ﬂow rate of 30 μL/min) using a lipid-coated L1 sensorchip in
the Biacore-X100 (GE Healthcare) system as described earlier
[22,30]. Vesicles for SPR analysis were prepared at a concentration
of 0.5 mg/ml in 20 mM HEPES buffer, pH 7.4, containing 0.16 M
KCl, and were vortexed vigorously and passed through a 100-nm
polycarbonate ﬁlter using an Avanti Mini-Extruder (Avanti Polar
Lipids, Alabaster, AL) according to the manufacturer's protocol.
After washing the sensor chip surface with the running buffer
(20 mM HEPES, pH 7.4, containing 0.16 M KCl) PC/PE/PS/PI(4,5)P2
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PE/PS (60:20:20) vesicles were injected at 5 μL/min to the active
surface and the control surface, respectively, to achieve similar
response unit (RU) values (3500–4000 RU). To minimize non-
speciﬁc adsorption the control surface was also coated with 40 μL
of BSA (0.1 mg/ml in the running buffer) at a ﬂow rate of 5 μL/min,
and equilibrated for 20 min, before the injection of protein. The
competitive inhibitory effects of each compound were determined
by measuring the change in response unit (RU) of the SPR sen-
sorgrams of PH-domains (500 nM) in the absence/presence of
compounds (0–20 μM) at a ﬂow rate of 30 μL/min. For inhibition
studies of CIP-4 with different PH domains the range of con-
centration was 0–200 μM. The compounds were equilibrated with
respective PH-domain for 30 min before any SPR measurements.
The decrease in RU value of each sensorgram with various com-
pound concentrations was measured to calculate % of inhibition
efﬁciency. The inhibition potencies were calculated as (1(RU of
protein mixed with chemicals/RU of protein only))100%. The RU
value after 180 s of injection was considered for % of inhibition
efﬁciency calculations. The IC50 values for this SPR analysis were
calculated using nonlinear least square ﬁt analysis (using an
equation, Req¼Rmax/(1þKd/A0) considering a Langmuir-type
binding model between the protein (A) and vesicles (B) i.e.
AþB2AB. Each experiment was repeated more than three times.
2.4. In-silico molecular docking analysis
Computational docking and scoring studies of the interaction of
the compounds with PH-domains were performed using Molegro
Virtual Docker (version 4.3.0, Molegro ApS, Aarhus, Denmark) and
AutoDock 4 (The Scripps Research Institute, La Jolla, USA) software
with essentially the same results [25,27]. The crystal structure of
AKT1-PH (1-116 amino acids, PDB ID: 1H10) and PLCδ1-PH (1-131
amino acids, PDB ID: 1MAI) was utilized for docking analyses
[31,32]. To generate apo-protein, the ligands were ﬁrst removed
from the co-crystal structures and then they were processed by
energy minimization. In the meantime energy minimized three-
dimensional structures of ligands were prepared by using the
GlycoBioChem PRODRG2 Server (http://davapc1.bioch.dundee.ac.
uk/prodrg/). The GROningen MAchine for Chemical Simulations
(GROMACS) library of three-atom combination geometries em-
ploying a combination of short molecular dynamics simulations
and energy minimizations were utilized for the conversion of 2D
molecular structures to 3D structures. The original blind-docking
parameters (selected binding site for docking/grid was chosen to
cover the entire PH domain; Grid coordinates were X¼22, Y¼16,
Z¼12, r¼30) were used in combination with an evaluation
scheme based on Gibbs free energy change (ΔG). In each docking
run, 100 docked structures were generated for individual ligand.
Energetically favored docked conformations were evaluated on the
basis of moledock and re-rank score. The docking poses were ex-
ported and examined with PyMOL software (The PyMol Molecular
Graphics System, Version 1.0r1, Schrödinger, LLC.). The residues
surrounding the compounds were also analyzed using LigPlot
provided by the European Bioinformatics Institute.
2.5. Circular dichroism studies
The circular dichroism (CD) spectroscopy was studied on a
JASCO J-815 CD spectropolarimeter at room temperature [33]. CD
spectra of PLCδ1-PH domain (1 μM) in the absence and presence of
compounds (1:3 molar ratio of the PLCδ1-PH domain to the com-
pounds) were obtained in the wavelength range of 190–245 nm in
10 mM phosphate – containing 10 mM NaCl buffer (pH 7.2).2.6. Anisotropy measurement
Fluorescence anisotropy measurements were performed on a
Fluoromax-4 spectroﬂuorometer at 25 °C. The anisotropies of 1,6-
diphenyl-1,3,5-hexatriene (DPH) and NBD-PE under liposomal
environment were measured according to the reported procedure
[25,27,34]. The ﬂuorescence probe DPH was incorporated into the
PC/PE/PS (60:20:20) liposome (100 μL of 0.5 mg/mL of total lipid)
by adding the dye dissolved in tetrahydrofuran (THF, 1 mM) to
vesicles up to a ﬁnal concentration of 1.25 μM. The NBD-PE probe
was incorporated to the PC/PE/PS/NBD-PE (59:20:20:1) liposome
using our earlier mentioned procedure [27]. After 30 min of in-
cubation at room temperature, DPH (λex¼355 nm; λem¼430 nm)
and NBD (λex¼460 nm; λem¼535 nm) ﬂuorescence anisotropies
were measured. The concentration of compounds was 15 μM. The
degree of anisotropy in the DPH/NBD ﬂuorescence of the probes
was calculated using Eq. (1), at the peak of the ﬂuorescence
spectrum, where IVV and IVH are the ﬂuorescence intensities of the
emitted light polarized parallel and perpendicular to the excited
light, respectively, and G¼ IVH/IHH is the instrumental grating fac-
tor.
r
I GI
I GI2 1
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2.7. Zeta-potential measurement
The zeta-potential measurements of the liposomes in the ab-
sence and presence of the compounds were carried out in aqueous
medium (at 25 °C, in 20 mM Tris–HCl buffer, pH 7.4, containing
0.16 M NaCl) using a Zetasizer Nano ZS90 (Malvern, Westborough,
MA) light scattering spectrometer equipped with a He–Ne laser
working at 4 mW (λ0¼632.8 nm) [35,36]. Unilamellar vesicles
composed of PC/PE/PS/PI(3,4,5)P3 (57:20:20:3) lipids were pre-
pared in 20 mM Tris–HCl buffer, pH 7.4, containing 0.16 M NaCl by
vigorous vortexing and extruding through a polycarbonate ﬁlter
(100-nm) using an Avanti Mini-Extruder. 100 μL of liposomes from
0.5 mg/mL of total lipid was used for zeta-potential measure-
ments. All the measurements were performed three times per
sample and averaged to give the ﬁnal value.
2.8. Förster resonance energy transfer (FRET) measurements
Analysis of protein-to-membrane Förster resonance energy
transfer (FRET) based binding assay was used to detect the se-
lectivity of the compounds for PH-domain binding through PIP-
binding site and detect the effectiveness of the compounds under
liposomal environment [25,27]. The vesicles composed of PC/PE/
PS/dPE (59:20:20:1) and PC/PE/PS/dPE/PI(4,5)P2 (56:20:20:1:3)
were used as control and for ligands, respectively. In this assay,
PLCδ1-PH domain was allowed to bind to the liposome and then
efﬁcacy of the compounds to displace the protein from membrane
surface was tested by monitoring the change in FRET signal in the
presence of the compounds. The FRET signal due to PIP-dependent
protein binding to the liposomes was corrected with non-speciﬁc
ﬂuorescence signal originated from control liposome (PC/PE/PS/
dPE) and protein interactions. The stock solution of compounds
was titrated into the sample containing PLCδ1-PH domain (1 μM)
and excess liposome (100 μM total lipid) in a buffer solution
(20 mM Tris–HCl buffer, pH 7.4, containing 0.16 M NaCl) at room
temperature. The competitive displacement of protein from the
membrane was monitored using protein-to-membrane FRET sig-
nal (λex¼280 nm and λem¼505 nm). Control experiments were
performed to measure the dilution effect under similar experi-
mental condition and the increasing background emission arising
Fig. 1. Structures of the compounds (CIPs) used in the present study.
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the protein and compound binding to the dPE lipid (present in
liposome) was also measured as control experiment. Protein-to-
membrane FRET signal values as a function of compound con-
centration were subjected to nonlinear least-squares-ﬁt analysis
using Eq. (2) to calculate apparent equilibrium inhibition constants
(KI(Compound)app) for compounds, where [x] represents the total
compound concentration and ΔFmax represents the calculated
maximal ﬂuorescence change
⎛
⎝
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2.9. Isothermal titration calorimetric (ITC) measurements
Thermodynamic parameters of protein–ligand interactions
were measured using an ITC-200 micro-calorimeter from Microcal
(Northampton, MA, USA). PLCδ1-PH domain (200 μM), after dia-
lysis with 20 mM HEPES buffer, pH 7.4, containing 0.16 M KCl, was
titrated against compounds (2 mM) dissolved in the ﬁnal dialysate
[37]. A typical titration involved injecting 20 injection volumes
(2 μL) of compound into the sample cell containing PLCδ1-PH
domain (201.6 μL) at 2.0 min intervals with continuous stirring (at
25 °C with stirring speed of 500 rpm). The heat of dilution data
corresponding to individual injections was analyzed using a se-
quential binding model with one binding site considering both IP3
and PS-binding sites per PLCδ1-PH domain monomer with the
system running Microcal Origin 7.0 software. The ΔH and ΔS va-
lues were obtained using a nonlinear least-square ﬁt of the data.
Gibbs free energy (ΔG) was calculated by using Gibbs equation:
ΔG¼ΔHTΔS.
2.10. Liposome binding assay
Inhibition of PI(4,5)P2/PLCδ1-PH domain interaction by the
compounds was further determined by liposome pull-down assay
according to the reported procedures [26,38,39]. Liposomes of PC/
PE/PS (60:20:20) and PC/PE/PS/PI(4,5)P2 and PC/PE/PS/PI(3,4,5)P3
(57:20:20:3) in 50 mM Tris buffer, pH 7.4, containing 150 mM
NaCl, 170 mM sucrose, pH 7.4 buffer solution were prepared by
sonication, followed by extrusion through 0.1 mm pore size poly-
carbonate ﬁlters. The suspension was pelleted down at 100,000g,
4 °C, for 20 min and resuspended in binding buffer (20 mM Tris
buffer, pH 7.4, containing 100 mM KCl, 5 mM MgCl2). Puriﬁed
PLCδ1- and AKT1 PH domains (50 μM) in the absence or presence
of compounds were incubated with sucrose-loaded vesicles (40 mg
in 100 mL) for 30 min in the presence of binding buffer containing
0.3 mg mL1 BSA. Control experiment of PLCδ1 binding to PC/PE/
PS liposome was also performed using the same method. Mem-
brane-bound protein was separated from free protein by cen-
trifugation at 100,000g for 30 min at 4 °C. Protein of supernatant
and pellet fractions was analyzed by SDS-PAGE gel.
2.11. Cellular translocation measurements
Human lung cancer cells (A549) were cultured according to the
American Type Culture Collection (ATCC) instructions. Cells were
grown in RPMI-1640 medium on cover slip supplemented with
10% heat inactivated FBS along with penicillin and streptomycin at
37 °C with 5% CO2. After 24 h of seeding the cells, GFP-tagged
PLCδ1-PH domain construct was transfected using poly-
ethylenimine transfection reagent in Opti-MEM media, according
to the manufacturer's instructions. Transfected media was chan-
ged with complete media after 24 h of transfection. Just before the
compound treatment (compounds were ﬁrst dissolved in DMSOand then diluted in Opti-MEM media, so that DMSO concentration
was o5% (v/v)), the media were removed and the cells were
washed and overlaid with serum free media. Cells were treated
with different concentration (5, 10, 20, 100 mM) of CIP-1 and CIP-4
for 30 min. For immunoﬂuorescence study, cells were ﬁrst washed
three times with phosphate-buffered saline (PBS) to remove the
media completely. Then, cells were ﬁxed using 4% paraformalde-
hyde solution at room temperature for 15 min. Fixed cells were
washed three times with PBS to remove the extra paraformalde-
hyde and were then permeabilized using 0.1% Triton X-100 solu-
tion for 10 min at room temperature. Following permeabilization,
the cells were again washed three times with PBS and mounted
with mounting media containing DAPI on a glass slide. Confocal
images of the ﬁxed cells were collected on Zeiss LSM 510 NLO
confocal microscopes (Carl Zeiss, Inc.) using 631.4 NA oil ob-
jective. For excitation of GFP and the green membrane marker, the
argon laser at 488 nm was used.3. Results and discussion
Phosphatidylinositol signaling pathway is considered as one of
the most commonly deregulated pathways in several human dis-
eases including cancer [5,20,40,41]. For this reason development of
potent and speciﬁc inhibitors for the effector proteins associated
with this PI-kinase/phosphatase pathway is highly demanding in
the drug discovery and related research ﬁelds [42]. However, tar-
geting the catalytic domain of these enzymes to develop inhibitor
remained quite challenging. For example, several potent inhibitors
of AKT1 enzyme turn out to be relatively toxic, presumably due to
the inhibition of other ser/threonine kinases [20,43]. On the other
hand, small molecules such as DPIEL and perifosine developed for
the inhibition of PIP/PH-domain interaction are comparatively
nontoxic and offer a better therapeutic strategy than inhibitors for
ATP-site [21,41]. In recent years, studies have been carried out to
identify phosphate or nonphosphate containing small molecules
as being inhibitors for PIP-binding domains [8,20,44,45].
It is well documented that stimulated PLCδ1 enzyme hydro-
lyzes PI(4,5)P2 to DAG and IP3, which acts as second messengers.
Dysregulation of PLC enzyme activity is related with diverse dis-
eases including cancer, cardiovascular diseases [46–48]. Therefore,
development of small molecule-based inhibitors is considered as
potential pharmacological tools to investigate the roles PLC en-
zyme in diseases and can be used as candidates for drug discovery.
The interaction of PH domain with PI(4,5)P2 at the inner PM is
essential for PLCδ enzyme to hydrolyze PI(4,5)P2 [17,29,49]. In this
regard, we have synthesized 1,2,3-triazol-4-yl methanol deriva-
tives targeting the PI(4,5)P2 binding PH-domain of PLCδ1 (Fig. 1).
The compounds were synthesized according to the reported pro-
cedure using CuO nanoparticles as catalyst [50–52]. Typically, all
molecules were designed such a way, that there must be 1,2,3-
triazol-4-yl methanol moiety, which are critical in forming more
Fig. 2. Amino-acid sequence alignment of the AKT1, GRP1, TAPP1, PLCδ1-PH domains is shown using Clustal X. Secondary structural elements of the PH domains are shown
below the alignments with colored pink (β-sheets) or blue (α-helices). PH domain residues forming the cationic patch at its base are labelled with chocolate squares.
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the shallow positively charged binding pocket of the PLCδ1-PH
domain (Fig. 2). The nitro group and an additional triazole ring
were installed to understand their impact in hydrogen bond for-
mation with the amino acid residues within the PH-domain
binding pocket. Thus, the impact of this study is not only inhibi-
tion constant measurement but also elucidate their binding
mechanism.0
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We ﬁrst measured the efﬁciency of the compounds in dis-
rupting the PIP/PH domain interaction, by using SPR-based com-
petitive binding assay, a useful technique for quantitative de-
termination of binding and/or inhibition afﬁnities in real-time
[20,30]. All SPR measurements were performed using two parallel
ﬂow-channel systems (control and active channel). Liposomes of
PC/PE/PS (60:20:20) and PC/PE/PS/PI(4,5)P2 or PC/PE/PS/PI(3,4)P20
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Table 1
Relative inhibitory activity of the compounds measured by competitive-surface plasmon resonance analysis.
Protein Relative inhibitory activity (%) IC50 values (nM)
CIP-1 CIP-2 CIP-3 CIP-4 CIP-1 CIP-2 CIP-3 CIP-4
PLCδ1-PH 8374 6273 – 7273 11377 159711 – 5379
TAPP1-PH 1872 4174 – 2172 647733 10678 – 1112778
AKT1-PH 4472 5572 471 3373 175721 315732 NM 3799798
GRP1-PH 5673 5875 – 5274 145711 21679 – 789735
Protein, 500 nM; % of inhibition was calculated using 5 μM compound concentration; measurements were performed in 20 mM HEPES buffer at pH 7.4 containing 160 mM
KCl; NM, not measured; liposome composition of PC/PE/PS/PIP (57:20:20:3) was used. The inhibition of PI(4,5)P2/PLCδ1-PH, PI(3,4,5)P3/AKT1-PH, PI(3,4,5)P3/GRP1-PH and PI
(3,4)P2/Tapp1-PH interactions was measured in the presence of compounds. Values represent the mean7SD from triplicate measurements.
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active channel, respectively. For all measurements only protein or
protein equilibrated with CIP compounds were passed over con-
trol channel to active channels. To remove any non-speciﬁc bind-
ing of protein on the liposomal surface, RU of control channel was
subtracted from RU of active channel. PIP selectivity, of the re-
spective PH domains was also tested under similar experimental
conditions. PLCδ1-PH domain does not bind to the PC/PE/PS/PI
(3,4,5)P3 (57:20:20:3) surface. The calculated % of inhibition values
from SPR measurements showed that compounds CIP-1 and CIP-4
strongly inhibit the PI(4,5)P2/PLCδ1-PH domain interaction under
liposomal environment (Fig. 3A). The compounds CIP-1 and CIP-4
with 5 μM concentration showed 83% and 72% inhibitory effect for
PI(4,5)P2/PLCδ1-PH domain interactions, respectively (Table 1). For
further understanding of this inhibitory effect of the compounds
on PI(4,5)P2/PLCδ1-PH domain interaction, we also carried out SPR
measurements in a concentration dependent manner (Fig. 3B and
C). The analysis clearly showed that the relative RU values of the
SPR sensorgrams of PLCδ1-PH domain decrease as a function of
concentration of the compounds. These results clearly suggest that
the compounds, CIP-1 and CIP-4 could affect the PI(4,5)P2 /PLCδ1-
PH domain interaction, either by blocking the binding site or by
altering the protein conformation.
The calculated IC50 values for CIP-1 and CIP-4 compounds were
113 and 53 nM, respectively for the PI(4,5)P2/PLCδ1-PH domain
interaction, indicating their strong binding pattern under experi-
mental conditions. PLCδ1-PH domain is reported as cellular mar-
ker of PI(4,5)P2 lipid [2,9,15,29]. To determine the selectivity of
potent compounds in inhibiting the PI(4,5)P2/PLCδ1-PH domain
interaction, we also measured their inhibitory effect on other PIPs
binding PH-domains (Fig. S1). It is well documented that AKT1-PH
domain strongly interacts with both PI(3,4,5)P3 and PI(3,4)P2,
whereas GRP1 and TAPP1-PH domains selectively interact with PI
(3,4,5)P3 and PI(3,4)P2 respectively [22]. We measured the in-
hibitory effects of compounds CIP-1 and CIP-4 on PI(3,4,5)P3/
AKT1-PH domain (IC50 values were 175 and 3799 nM, respec-
tively), PI(3,4,5)P3/GRP1- PH domain (IC50 values were 159 and
789 nM, respectively) and PI(3,4)P2/TAPP1-PH domain (IC50 values
were 647 and 1112 nM, respectively) interactions (Table 1). Con-
centration dependent % of inhibition values of CIP-4 for different
PIP/PH domain interactions are shown in Table S1. We also used
compound (1-methyl-1H-1,2,3-triazol-4-yl)methanol as negative
control for competitive SPR measurements (data not shown). This
compound contain triazole ring as of our tested compounds (CIPs)
but did not affect the PLCδ1-PH domain binding to the PC/PE/PS/PI
(4,5)P2 liposome under similar experimental conditions. This
clearly states that certain structural units of the tiazole ring are
essential for signiﬁcation inhibition of PI(4,5)P2/PLCδ1-PH domain
interactions. We also performed SPR analysis with only com-
pounds (in the absence of protein) on liposome coated surface to
examine the effect of compounds on this competitive-SPR analysis
(Fig. S2). The sensorgrams showed almost no signiﬁcant binding of
the compounds on liposome surface (PC/PE/PS/PI(4,5)P2). Thissuggests that only compound do not have any effect on the RU of
the PLCδ1-PH domain binding to the PI(4,5)P2 containing
liposome.
These results suggest that compound CIP-4 has certain degree
of selectivity for PI(4,5)P2 binding PLCδ1-PH domain over PI(3,4)P2
and PI(3,4,5)P3 binding PH-domains. Differential inhibitory effects
of the compounds on PIP/PH-domain interactions could be due to
their interaction pattern with the amino acid residues within and/
or outside the PIP-binding pocket, stability of the compound–PH-
domain complexes, effect of compound on membrane bilayer or
their synergistic effect. Hence, additional studies are required to
determine the speciﬁcities and understand their binding me-
chanism of these compounds for diverse PIP-binding PH-domains.
3.2. Molecular docking analysis
The SPR-based competitive binding assay showed that the
compounds differentially inhibit the PI(4,5)P2/PLCδ1-PH domain
interaction under the similar experimental conditions. The relative
inhibitory activity of compound CIP-4 for PI(4,5)P2/PLCδ1-PH do-
main was much higher than other PIP-binding PH-domains, which
indicate that CIP-4 was able to distinguish different PH-domains
tested under the similar experimental conditions. Structural ana-
lysis revealed that all these tested compounds contain 1,2,3-tria-
zol-4-yl methanol moiety, consequently to elucidate the probable
binding mode for different inhibitory efﬁcacies, molecular docking
analysis was performed.
The reported crystal structure of PLCδ1-PH domain (1MAI) in
complex with inositol 1,4,5-triphosphate (IP3) provides a detail
insight into the mode of ligand interactions within the binding
pocket [32]. IP3 is the only headgroup of PI(4,5)P2 lipid molecule.
Structural analysis and structure-activity studies showed that
phosphate groups attached to myo-inositol ring of IP3 preferably
interact with the K30, K32, W36, R40, S55, R56 and R57 residues
through hydrogen bond formation [10,15,29,32]. More than 90% of
the docking poses of the blind-molecular docking analysis (gird
covers the whole protein) revealed that CIP-1 and CIP-4 ligands
preferably interact with the PLCδ1-PH domain through its IP3
binding site. For further analysis best docking poses were selected
based on moldock score, rerank score and position within the IP3-
binding site of the protein. The calculated in-silico interaction
energies between the ligands and PLCδ1-PH domain protein are of
high negative values, suggesting acceptable docking poses for
further analysis (Table S2). The triazol ring, hydroxy and nitro
groups of the compounds could be mainly responsible for their
interaction with the cationic groove of the PLCδ1-PH domain
(Fig. 4). The docking poses showed that the pharmacophores of
compounds CIP-1 and CIP-4 could form hydrogen bonds with the
side chain or backbone carbonyls/amide protons of PLCδ1-PH
domain through its IP3 binding site (Fig. 4 and Fig. S3).
However, the docking results did not show any signiﬁcant dif-
ference in their number of interactions or interacting residues.
CIP-1 and CIP-4 showed 5 and 6-hydrogen bond formation with
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Fig. 4. Structure of PLCδ1-PH domain (1MAI) in complex with IP3 (A). Model structures of ligands CIP-1 (B) and CIP-4 (C) docked into the PIP-binding site of the PLCδ1-PH
domain (1MAI). Residues involved in interactions through hydrogen bond formation are shown using dashed lines (pink).
S. Gorai et al. / Biochemistry and Biophysics Reports 2 (2015) 75–86 81the PLCδ1-PH domain, respectively (Fig. S3). Calculated IC50 values
of the compounds showed that CIP-4 has approximately 2-fold
stronger binding afﬁnity than CIP-1. Therefore, strength of inter-
actions and surface area of the compounds may be important
criterion in showing stronger binding properties. We also per-
formed molecular docking analysis of these ligands with AKT1-PH
domain (1H10) [31]. The docking results showed that the ligands
speciﬁcally interact with the AKT1-PH domain through its IP4-
binding site in a similar pattern as with PLCδ1-PH domain. In
particular, compound CIP-4 forms only 3-hydrogen bonding with
AKT1-PH domain, which was also reﬂected in its IC50 values.
Therefore, the molecular docking analysis predicts that these li-
gands interact with the PH-domain preferably through their PIP-
binding site.
3.3. Structural change measurement
Lower IC50 values of the compounds could be due to the
structural change of the PH-domains in the presence of the com-
pounds that could prohibit the PH-domains to interact with the
PIP containing membranes. In this regard, we performed circular
dichroism (CD) spectral analysis to understand whether interac-
tions of compounds with the PH-domains alter the structural in-
tegrity or not. The CD spectra of the PLCδ1-PH domain (1 μM) in
the absence/presence of compounds CIP-1 and CIP-4 are shown in
Fig. 5A. The negative ellipticity in the range of 225–200 nm and
the positive ellipticity around 195 nm are the characteristic of
protein secondary structural features such as α-helix and β-sheet.-4
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Fig. 5. Effect of compounds on the secondary structural content of the PLCδ1-PH doma
compounds (20 μM) in 10 mM phosphate – containing 10 mM NaCl buffer (pH 7.2) (A)
pounds (20 μM, at t¼5 min) in aqueous solution (PBS buffer pH 7.0) at 25 °C (B). PLCd1The spectral data showed that in the presence of compounds CIP-1
and CIP-4 there is almost no change in their secondary structural
pattern of PLCδ1-PH domain in the far UV-CD spectrum. The
change in beta sheet content is little bit higher in the presence of
CIP-4 than CIP-1, which is in correlation with the IC50 values.
However, larger change in β-sheet content of the PLCδ1-PH do-
main indicates that the compounds interact with the PH-domain
through its IP3-binding site which is composed of seven β-sheets
and connecting loop regions and stabilizes the PLCδ1-PH domain
structure than in free dynamical structure. It is important to
mention that any increase in helical content of the PLCδ1-PH
domain upon ligand binding would be small and that any increase
in CD-signal in the range of 225–200 nm might be obscured by the
change in contribution from high β-sheet content of the PH-do-
main structure. Therefore CD analyses clarify that these com-
pounds neither induce protein aggregation nor signiﬁcantly de-
stabilize the 3D-structure of the protein.
In order to ascertain that ligand binding does not induce any
signiﬁcant structural change (such as oligomerization) of the
PLCδ1 PH-domain protein (1 μM), we also performed dynamic
light scattering (DLS) measurements in aqueous solution (at 25 °C,
in 20 mM Tris–HCl buffer, pH 7.4, containing 0.16 M NaCl). Fig. 5B
shows that in the presence of compounds sizes (diameter) of the
particles are slightly different. Therefore, our CD and DLS mea-
surements clearly showed that the ligand binding does not sig-
niﬁcantly alter the secondary structure of the PLCδ1-PH domain
and no oligomerization was observed under the experimental
conditions, respectively.0
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Another possibility of the lower IC50 values of the compounds
could be also due to their interaction with the membrane as was
seen in the case of neomycin [29]. It can be assumed that direct
interaction of the compounds with the PIP-containing liposomes
can alter the membrane dynamics and inhibit the PH-domains to
interact with the membranes. Therefore, to understand whether
the compounds alter the membrane dynamics of lipids and ﬂuidity
of the lipid bilayer, we measured the ﬂuorescence anisotropy of
1,6-diphenyl-1,3,5-hexatriene (DPH) and 1,2-diphytanoyl-sn-gly-
cero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-
yl) (NBD-PE) under liposomal environment [27,34]. The mem-
brane composition used for the SPR studies contain anionic lipids
like PS and PIP. We presume that the interaction of the triazole and
nitro groups of the compounds with the anionic lipids could alter
the membrane organization by blocking the protein binding under
the liposomal environment and allowing the competitive-SPR
measurements to show high inhibitory effect by the compounds.
The DPH molecules generally embedded within the hydrophobic
core of the lipid bilayer, NBD of NBD-PE is presumed to be mainly
localized at the membrane interface (Fig. S4) therefore changes in
ﬂuorescence anisotropy values can be useful in evaluating the
modulation of lipid-bilayer ﬂuidity induced by membrane-active
compounds. We used membrane localized DAG16 molecule as a
positive control for this measurement. Fig. 6 and Table S3 re-
present the change in anisotropy values of DPH and NBD-PE mo-
lecules in the presence of anionic hybrid lipids under liposomal
environment. NBD ﬂuorescence anisotropy was also measured in
the presence of different compound concentrations (Fig. S5). The
variations in DPH ﬂuorescence anisotropy values affected by the
compounds are very small, indicating almost no change in order-
ing of the core of lipid bilayer. However, NBD ﬂuorescence aniso-
tropy values get affected only at higher concentrations of the
compounds. This indicates that ordering of the interfacial region of
the lipid bilayer gets affected by the compounds only at higher
concentrations. The anisotropy measurements were performed at
25 °C, which is much above the phase transition temperature of
PC/PE/PS (60:20:20) lipid bilayers. Therefore, the lipid mixture is
in liquid-crystal (LC) phase at 25 °C [27,53]. We also measured the
change in surface potential of the liposomes (PC/PE/PS/PI(4,5)P2)
in the absence and presence of the compounds, to determine
whether their interaction could alter the surface charge of the
liposmes. The results clearly showed that the compounds have0
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Fig. 6. Fluorescence anisotropy of DPH and NBD-PE embedded in PC/PE/PS (60:20:20)
Control: no ligand was added to the liposomes. Zeta potential of the PC/PE/PS/PI(4,5)P2 (
(B). 100 μL of liposomes from 0.5 mg/mL of total lipid was used for all measurements. Vweak effect on the surface potential values of the liposomes, in-
dicating their weak interaction pattern with the negatively
charged membrane surface (Fig. 6). Therefore, the stronger in-
hibitory effects of the compounds could be predominantly due to
its stronger binding with the respective PH-domains.
3.5. Förster resonance energy transfer analysis
The membrane binding surface surrounding the IP3-binding
site of the PH domain allows PLCδ1 to interact with the cellular
membranes [37]. This PI(4,5)P2 dependent membrane interaction
of the PLCδ1-PH domain activates PLCδ1 enzyme [18]. Therefore,
for further understanding of the selectivity of these compounds in
inhibition of the PI(4,5)P2/PH-domain interactions, we performed
competitive-protein to membrane Förster resonance energy
transfer (FRET) analysis. One of the Trp-residues (W27) is localized
close to the IP3-binding site of the PLCδ1-PH domain and provides
as FRET donor, and a low density of membrane-embedded, 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(5-dimethylami-
no-1-naphthalenesulfonyl) (dPE) lipid serve as the FRET acceptor.
In this assay we ﬁrst allowed the PH-domain to bind the dPE la-
beled PI(4,5)P2 containing liposomes, then the compounds were
added to conﬁrm that they interact with the PH domain through
its PIP-binding site. The PC/PE/PS/dPE (59:20:20:1) and PC/PE/PS/
dPE/PI(4,5)P2 (56:20:20:1:3) liposomes were used as control and
for ligands, respectively. The FRET signal due to PI(4,5)P2-depen-
dent protein binding to the liposomes was corrected with non-
speciﬁc ﬂuorescence signal originated from control liposome (PC/
PE/PS/dPE) during only protein and compound binding. The de-
crease in ﬂuorescence signal at 505 nm wavelength in the pre-
sence of compounds conﬁrmed its binding to PLCδ1-PH domain
under liposomal environment (Fig. 7). However, detailed spectral
analysis showed a concomitant decrease of Trp-ﬂuorescence signal
(at 340 nm). We tested the effect of CIP-1 and CIP-4 on Trp- and
dasyl ﬂuorescence. Our control experiment showed that the
compounds directly interact with the PLCδ1-PH domain in solu-
tion (data not shown). Therefore, the decrease in protein-to-
membrane FRET signal could be predominantly due to compound
dependent Trp-ﬂuorescence quenching of the protein. The de-
crease in FRET signal was also examined to calculate apparent
inhibitory constant (KI(Compound)app] using Eq. (2). Calculated
KI(Compound)app values for CIP-1 and CIP-4 were 60.4 and
9.9 μM, respectively, demonstrating that CIP-4 efﬁciently and
speciﬁcally inhibits PI(4,5)P2/PLCδ1-PH domain interactions under-40
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Fig. 7. Representative protein-to-membrane FRET experiment under liposomal environment. Addition of increased concentration of compounds, CIP-4 (A) to PLCδ1-PH
domain (2 μM) bound to the active liposome (PC/PE/PS/dPE/PI(4,5)P2 (56:20:20:1:3)) decreases the FRET signal at 509 nm. Competitive displacement assay for the PLCδ1-PH
domains (2 μM) bound to PC/PE/PS/dPE/PI(4,5)P2 liposome. The bound complex was titrated with the CIP-1 and CIP-4. All the measurements were performed in 20 mM Tris,
pH 7.4 containing 160 mM NaCl. Compound concentrations were varied from 0 to 70 μM. PLCd1 stands for PLCδ1.
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3.6. Isothermal titration calorimetric measurements
To better understand the binding mechanism of the com-
pounds, CIP-1 and CIP-4 with the PLCδ1-PH and AKT1-PH do-
mains, we performed isothermal titration calorimetric (ITC) mea-
surements. Representative titration plots of both the compounds
with PLCδ1-PH domain showed an exothermic reaction with one-
step binding mechanism (Fig. S6). This indicates that stronger
hydrogen bond formation and van der Waals interactions between
the compounds and cationic groove present inside the PIP-binding
site of the PLCδ1-PH domain are predominant factors for their
interactions. The binding parameters are in accordance with
spectroscopic and molecular docking analysis results. Interactions
of both the compounds with AKT1-PH domain followed an exo-
thermic reaction with two-step binding mechanism (Fig. S6).
However, both the compounds have weaker binding afﬁnity for
AKT1-PH domain in comparison with the PLCδ1-PH domain.
Therefore, ITC analysis clearly suggests that the compounds in
solution interact with the PLCδ1-PH and AKT1-PH domain.
3.7. Lipid-pull down assay
The inhibition of PI(4,5)P2/PLCδ1-PH domain interaction under
liposomal environment was also qualitatively determined by lipid
pull-down assay [26,38,39]. The binding of PLCδ1-PH domain
(50 μM) with PI(4,5)P2 containing liposomes (PC/PE/PS/PI(4,5)P2
(57:20:20:3)) was measured in the absence or presence of com-
pounds (100 μM), CIP-1 and CIP-4 at physiological pH. The coo-
massie blue staining of the SDS-PAGE gel clearly showed that the
PLCδ1-PH domain binding to the PI(4,5)P2 containing liposomes1 2             3          4          5             6
Compound        - - CIP-4   CIP-4 CIP-1   CIP-1
PLCδ1 PH          +            +         +          +         +          +       
PF          SF       PF        SF       PF         SF
Fig. 8. Coomassie blue stained SDS-PAGE gel images of liposome binding assay. PC/
PE/PS/PI(4,5)P2 (57:20:20:3) liposome was used for PLCδ1-PH domain binding
study. Lanes 1, 3 and 5 were liposome bound fraction and 2, 4 and 6 were unbound
fraction of PLCδ1-PH domain. Compound CIP-1 and CIP-4 were used as inhibitor.
Liposome concentration 100 μM; Protein concentration 50 μM; Compound con-
centration, 100 μM; PF, palate fraction; SF, soluble fraction.was almost completely diminished by the compound CIP-4
(Fig. 8). However, compound CIP-1 was not that efﬁcient in dis-
placing the PLCδ1-PH domain from its liposome bound state. The
inhibition of PI(3,4,5)P3/AKT1-PH domain interaction by the po-
tent compounds was also measured using similar methods. Visual
inspection of coomassie blue stained SDS-PAGE gel images re-
vealed that compound CIP-1 inhibits the PI(3,4,5)P3/AKT1-PH
domain interaction more strongly than compound CIP-4, under
similar experimental conditions (Fig. S7A). Control experiment
showed that PLCδ1-PH domain has very weak binding afﬁnity for
PC/PE/PS liposome (Fig. S7B). Hence, the liposome-pull down as-
say results indicate that the PLCδ1-PH domain strongly interacts
with PI(4,5)P2 containing liposomes and CIP-4 strongly inhibits
the PI(4,5)P2/PLCδ1-PH domain interaction.
3.8. Cellular translocation of PLCδ1-PH domain
To demonstrate the physiological signiﬁcance of our in vitro
inhibition/binding studies that show potent compounds strongly
interact with PLCδ1-PH domain and inhibits its speciﬁc interac-
tions with PI(4,5)P2 under liposomal environment, we measured
membrane displacement of GFP-tagged PLCδ1-PH domain in A549
cells. As reported earlier PI(4,5)P2 is mostly present at the inner
PM of cells, hence expression of cDNA of GFP-tagged PLCδ1-PH
domain allows this protein to be localized at the PM [9,15,54].
Freshly prepared compound solutions were added after 24 h of
transfection of cDNA. Cells were treated with compounds for
30 min and then ﬁxed with 4% paraformaldehyde for immuno-
ﬂuorescence study. All measurements were performed for mini-
mum three times with more than 10 cells were monitored for each
measurement. In general, more than 80% of cell population
showed similar behaviors with respect to PM displacement of
PLCδ1-PH domain. The extent of displacement of PLCδ1-PH do-
main from PM was monitored in the presence of compounds CIP-1
and CIP-4 (0–100 μM) in a concentration dependent manner
(Figs. 9 and S8). Confocal microscopic images clearly showed that
external addition of CIP-4 can efﬁciently displace localized PLCδ1-
PH domain from PM, whereas extent of displacement of PLCδ1-PH
domain from PM is lowered by compound CIP-1, which is ac-
cordance with their in vitro binding afﬁnities/IC50 values. The re-
sults indicate that the PI(4,5)P2/PLCδ1-PH domain interaction is
indeed inhibited by the potent compounds under cellular
environment.
GFP-PLCδ1-PH + + + +             
CIP-4 ; 0μM M 5μ 10 μM 20 μM 100 μM
Fig. 9. Effect of compound on cellular localization of GFP-tagged PLCδ1-PH domain in A549 cells. Representative cellular localization pattern of GFP-tagged PLCδ1-PH domain
in the absence or presence of compound CIP-4 with different concentrations, 0 (A), 5 (B), 10 (C), 20 (D) and 100 μM (E). The compound was treated in A549 cells for 30 min
and then cells were ﬁxed with 4% paraformaldehyde for immunoﬂuorescence study. More than 97% cells showed plasma membrane localization of GFP-tagged PLCδ1-PH
domain in absence of the compounds, whereas more than 80% (5 μM), 83% (10 μM), 86% (20 μM), and 95% (100 μM) of the observed cells showed preferential cytosolic
localization of GFP-tagged PLCδ1-PH domain at different compound concentrations.
S. Gorai et al. / Biochemistry and Biophysics Reports 2 (2015) 75–8684Present study described that compounds with 1,2,3-triazol-4-yl
methanol moiety had moderate to strong inhibition of the PI(4,5)
P2 binding to the PLCδ1-PH domain. Through biophysical analyses
demonstrate that the interactions between the potent compounds
and lipid bilayer are very weak in nature. The compounds pre-
ferably localize in the bulk phase of the solution and its pharma-
cophores are accessible for PH-domain binding under the experi-
mental conditions. The 1,2,3-triazol-4-yl methanol moiety and
nitro group are crucial for their interaction with the PH-domains.
These compounds have stronger binding afﬁnity for several PH
domains, but their afﬁnity differences are negligible except for
compound CIP-4. The higher binding afﬁnity of CIP-4 for PLCδ1-
PH domain over the other PH- domains including AKT1, TAPP1 and
GRP1 proteins could be due to its true selectivity. We hypothesize
that stronger binding of the compounds with the PLCδ1-PH do-
main blocks its membrane association and PI(4,5)P2 binding,
which is essential for its activity in hydrolyzing PI(4,5)P2 to IP3 and
DAG under cellular environment. However, the stronger binding
afﬁnity and selectivity for PLCδ1-PH domain of compound CIP-4
over CIP-1 could be because of the presence of additional triazole
ring, which not only provide additional hydrogen bonding with
the amino acid residues within the binding pocket but also the
surface area of the liagnd required for stronger inhibition of PI(4,5)
P2/PLCδ1-PH domain interactions.
Recently, neomycin is reported as inhibitor of PI(4,5)P2 binding
PLC enzyme, which regulates PI(4,5)P2 hydrolysis at the cellular
membranes, but the mechanism of its activity is quite different than
compound CIP-4 [29]. Strong electrostatic interactions between
neomycin and PI(4,5)P2 molecules present at the membranes reg-
ulate PLC enzyme activity. However, direct binding of neomycin to PI
(4,5)P2 can alter biological activities of several other proteins/en-
zymes including protein kinase C. U73122, ATA are among other
reported inhibitors of PLC enzyme, but these compounds targets
catalytic site of the enzyme [55,56]. Our experimental results show
that CIP-4 selectively interacts with the PH domain of PLCδ1 enzyme.
We hypothesize that the surface area of CIP-4 compound ﬁts prop-
erly within the IP3 binding site of PLCδ1-PH domain not with other
PH domains including that of AKT1 enzyme. Although competitive-
SPR and FRET analyses indicate that CIP-1 and CIP-4 presumably
interact through the IP3 binding site of the PLCδ1-PH domain butfurther detail analysis including mutation and activity studies re-
quired to prove the proper binding site of the compounds, which is
beyond the scope of the current study.
In this regard, we hypothesize that selective PLC enzyme ac-
tivity can be also controlled by these types of compounds, which
directly interacts with the PIP-binding domains not with the PIPs.
However, further biological studies, including enzyme activity as-
say, are required to understand the PI(4,5)P2/PH domain inhibition
potency of compound CIP-4 and regulation of PLC enzyme activity.4. Conclusion
Taken together, our results show that 1,2,3-triazol-4-yl methanol
derivatives strongly interact with PH-domain of PLCδ1, AKT1 and
GRP1 proteins but weakly interact with the model membranes. Po-
tent compound CIP-4 efﬁciently displaces PI(4,5)P2 from its binding
sites of the PH-domains, but failed to displace PI(3,4)P2 and PI(3,4,5)
P3 effectively from their respective PH-domain binding pockets, in-
dicating its selectivity for PI(4,5)P2/PH-domain interactions. The in-
teraction of the potent compounds with the PLCδ1-PH domain is
exothermic and does not alter its secondary structural content. The
molecular docking analysis indicates that the presence of two triazol
moieties and nitro group is essential for their interaction with the
PH-domains. The results suggest that these small molecules seem to
act principally by binding to the PH-domain and preventing the re-
cruitment to the cellular membranes, where these effector proteins
are primarily activated. Our ﬁndings also suggest that the 1,2,3-tria-
zol-4-yl methanol moiety can be used to develop nonphosphate-
based potential regulators for PI(4,5)P2 binding PH and other lipid
binding domains containing proteins.Acknowledgments
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